Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oncothyreon -- Ignore unavailable to you. Want to Upgrade?

To: StockMiser who wrote (594)	4/24/1999 9:15:00 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 2344

FWIW, another biotech that I follow, Vion, just had a CC at which they talked about their licensing deal with Boehringer Ingelheim. For $50M, BI gets world marketing rights outside of N.Amer. to Promycin(now in PIII). BI will pay licensing fees, development milestones and royalties on future sales outside of N.A. Vion mgnt. indicated that about $32M in milestone payments were back-ended -- following the NDA. Other items from the 11/97 news release: 1)Vion and BI will share development costs. 2)BI will make an equity investment in VION at a "premium to the current market price". My guess is that these are probably some "typical" terms. I do not know about the enrollment as a payment trigger, but it certainly could be. Jim